OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
In Memoriam Mahlon R. DeLong (1938–2024)	475
John Michael Walshe (April 24, 1920–October 14, 2022)	157
Issue Information	127
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	123
Movement Disorders: Volume 40, Number 2, February 2025	111
	106
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	93
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	93
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	87
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?	87
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	84
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	82
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating	79
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	78
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	74
A Multi‐center Genome‐wide Association Study of Cervical Dystonia	73
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy	72
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	71
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	68
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	65
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	64
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	63
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	63
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	63
May Infographic	63

Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	61
Mortality of People with Parkinson's Disease in a Large UK‐Based Cohort Study: Time Trends and Relationship to Disease Duration	60
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	60
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	58
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	57
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	57
Movement Disorders: Volume 37, Number 9, September 2022	56
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	56
Obituary for Jan O. Aasly (1950–2022)	56
Movement Disorders: Volume 36, Number 11, November 2021	53
Author Index	53
October Infographic	52
	52
Issue Information	51
Thank you to Reviewers 2022	51
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	50
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	50
Downbeat Nystagmus in Episodic Ataxia Type 1 Associated with a Novel KCNA1 Mutation	48
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	48
Reply to: “Application of the mPSPRS to the Salerno Cohort”	46
Diagnostic and Prognostic Value of External Anal SphincterEMGPatterns in Multiple System Atrophy	46
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation	46
Functional Movement Disorders and Drug‐Induced Movement Disorders	45
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	45
Issue Information	45
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	45
	45
The Lows of High Reward: Choking Under Pressure	42
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	42
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	42
Substantiating the Short Burst Duration in Cortical Myoclonus	42
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	42
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease	41
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	40
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”	40
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	40
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population	40
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	39
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	38
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	38
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis	38
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	37
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	37
Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia	37
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia	36
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	36
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	36
Issue Information	35
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	35
July Infographic	35

Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	34
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	34
Movement Disorders: Volume 40, Number 3, March 2025	34
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	34
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	34
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	34
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis	33
Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous MYORG Mutation	33
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	33
Tract‐Specific Spinal Cord Diffusion Tensor Imaging in Friedreich's Ataxia	33
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	33
A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics	33
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	33
Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation	32
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease	32
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	32
In Memoriam Gregor K. Wenning (1964–2024)	32
Teaching an Old Drug a New Trick for Dystonia	32
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	32
Putaminal y‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease	32
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	31
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	31
August Infographic	31
Ethnic Differences in Dystonia Prevalence and Phenotype	31
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	31
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	31
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy	31
Movement Disorders: Volume 38, Number 12, December 2023	30
Issue Information	30
Parkinsonisms	30
Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia—The SPASTOX Trial	30
Defining the Importance of Minor Hallucinations in Parkinson's Disease	30
Keyword Index	29
Issue Information	29
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	29
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	29
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	29
February Infographic	29
Issue Information	28
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders	28
Pain in Multiple System Atrophy: A Community‐Based Survey	28
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	28
Altered Spatiotemporal Dynamics of the Resting Brain in Mild Cognitive Impairment with Lewy Bodies	28
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	28
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	27
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009	27
Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder	27
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	27
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	27
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	27
COVID‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism	27
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	26
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	26
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	26
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	26
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	26
February Infographic	25
Pandemic Tic‐like Behaviors Following Social Media Consumption	25
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	25
Movement Disorders: Volume 38, Number 9, September 2023	25
Movement Disorders: Volume 39, Number 9, September 2024	25
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	25
	25
Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation	24
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	24
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	24
Issue Information	24
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	24
MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression	24
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	24
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	23
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	23
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	23
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	23
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease	23
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	23
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	23
Obituary for Professor Hiroshi Shibasaki	23
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	23
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	22

Learning to Have a Long‐Duration Response	22
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	22
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	22
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	22
Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo	22
Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?	22
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	21
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	21
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels	21
	21
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	21
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	21
Where Do Parkinson's Disease Patients Look While Walking?	21
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	21
Issue Information	21
Automated Motor Tic Detection: A Machine Learning Approach	21
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	21
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease	21
	21
The Gastrointestinal Dysfunction Scale for Parkinson's Disease	21
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	20
March Infographic	20
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	20
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	20
Movement Disorders: Volume 38, Number 11, November 2023	20
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	20
Prasinezumab: A Bayesian Perspective on Its Efficacy	20
Keyword Index	20
April Infographic	20
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	20
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis	19
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	19
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	19
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons	19
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease	19
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof‐of‐Principle Issues from a Randomized Controlled Study	19
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	19
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	19
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	19
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease	19
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	19
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	19
Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?	19
	18
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	18
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	18
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	18
	18
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	18
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis	18
Catatonia: What Else Matters?	18
Issue Information	18
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	18
Striatal Cholinergic Dysregulation after Neonatal Decrease in X‐Linked Dystonia Parkinsonism‐Related TAF1 Isoforms	18
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	18
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	18
Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria	17
Movement Disorders: Volume 36, Number 10, October 2021	17
Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus	17
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?	17
Cross‐Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease	17
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	17
Dysautonomia Is Associated with Cognitive Fluctuation in Dementia with Lewy Bodies	17
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	17
Advancing Parkinson's Research: Considerations and Future Directions	17
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism	17
A GNAI1 Pathogenic Variant in a Case with GNAO1‐Isolated Dystonia: A Modifier of Disease Severity?	17
Surgery Imaging and Technology	17
An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis	17
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family	17
Reply to: “A Primary Writing Tremor Is a Form of Dystonic Tremor: Is the Debate Settled?”	17
Motor Cortical Network Excitability in Parkinson's Disease	16
Diffusion Magnetic Resonance Imaging Microstructural Abnormalities in Multiple System Atrophy: A Comprehensive Review	16
Deep Brain Stimulation as an Exclusion Criterion in Parkinson's Disease Studies: Time to Rethink?	16
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	16
High Pesticide Exposure Events and Dream‐Enacting Behaviors Among US Farmers	16
Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients	16
IRF2BPL‐Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent	16
Viewpoint on Milestones for Fellowship Training in Movement Disorders	16
Aggregation‐Seeding Forms of α‐Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid	16
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome	16
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD	16
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study	16
Computerized Cognitive Training Increases Gray Matter Volumes in Huntington's Disease: A Pilot Study	16
Neurodevelopmental Gene‐Related Dystonia‐Parkinsonism with Onset in Adults: A Case with NAA15 Variant	16
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts	16
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	16
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial	16
Redefining Bradykinesia	16
Movement Disorders: Volume 38, Number 7, July 2023	15
	15